Highlight
• Povetacicept, a dual BAFF and APRIL inhibitor, significantly reduced proteinuria in IgA nephropathy by week 36. • Markers of disease activity such as galactose-deficient IgA1 and hematuria also improved substantially with therapy. • Adverse event rates were comparable between povetacicept and placebo groups, suggesting a favorable safety profile. • The trial underscores the pathophysiological role of BAFF and APRIL in IgA nephropathy and support targeting these pathways therapeutically.
